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Omega-3 polyunsaturated fatty acids (PUFAs) exhibit neuroprotective properties and
represent a potential treatment for a variety of neurodegenerative and neurological
disorders. However, traditionally there has been a lack of discrimination between the
different omega-3 PUFAs and effects have been broadly accredited to the series as a
whole. Evidence for unique effects of eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA) and more recently docosapentaenoic acid (DPA) is growing. For example,
beneficial effects in mood disorders have more consistently been reported in clinical trials
using EPA; whereas, with neurodegenerative conditions such as Alzheimer’s disease,
the focus has been on DHA. DHA is quantitatively the most important omega-3 PUFA in
the brain, and consequently the most studied, whereas the availability of high purity
DPA preparations has been extremely limited until recently, limiting research into its
effects. However, there is now a growing body of evidence indicating both independent
and shared effects of EPA, DPA and DHA. The purpose of this review is to highlight
how a detailed understanding of these effects is essential to improving understanding
of their therapeutic potential. The review begins with an overview of omega-3 PUFA
biochemistry and metabolism, with particular focus on the central nervous system (CNS),
where DHA has unique and indispensable roles in neuronal membranes with levels
preserved by multiple mechanisms. This is followed by a review of the different enzyme-
derived anti-inflammatory mediators produced from EPA, DPA and DHA. Lastly, the
relative protective effects of EPA, DPA and DHA in normal brain aging and the most
common neurodegenerative disorders are discussed. With a greater understanding of
the individual roles of EPA, DPA and DHA in brain health and repair it is hoped that
appropriate dietary recommendations can be established and therapeutic interventions
can be more targeted and refined.
Keywords: aging, Alzheimer’s disease, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid,
omega-3 fatty acids, Parkinson’s disease
Introduction
There is mounting evidence supporting the beneficial effects of an increased intake of omega-3
polyunsaturated fatty acids (PUFAs) in a variety of neurodegenerative and neurological conditions
(Dyall and Michael-Titus, 2008; Dyall, 2010; Denis et al., 2015). However, comparing results
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between studies has traditionally been hampered by a lack of
discrimination between the different omega-3 PUFAs and results
are typically attributed the omega-3 PUFAs as a whole (Dyall,
2011). There is accumulating evidence that certain effects may be
unique and specific to individual omega-3 PUFAs and there can
no longer be an assumption of equivalence in either mechanism
of action or function. This issue is particularly important when
pooling studies in systematic reviews and meta-analyses. For
example, two recent meta-analyses into the effects of EPA
and DHA in depression reviewed predominantly the same
studies, but produced substantially different outcomes (Sublette
et al., 2011; Bloch and Hannestad, 2012). Bloch and Hannestad
found only small, non-significant benefits, with no significant
differences between EPA and DHA (Bloch and Hannestad,
2012). Whereas Sublette and coworkers used a mixed-effect
model, separating the treatments by EPA content, and found
that only supplements with the proportion of EPA ≥ 60% of the
total EPA and DHA content in a dose range of 200–2200 mg
EPA in excess of DHA effective against primary depression
(Sublette et al., 2011). Although a number of methodological
differences between the meta-analyses may have contributed
to the different outcomes (Lin et al., 2012b); this incongruity
between findings highlights the importance of considering the
omega-3 PUFAs as biologically distinct molecules. Furthermore,
although current evidence suggests that EPA and DHA are the
predominant biological omega-3 PUFAs, the bioactive effects of
docosapentaenoic acid (DPA, 22:5n-3) are gaining recognition in
the literature (Kaur et al., 2011).
A number of excellent reviews have discussed the
complementary and divergent effects of the different omega-3
PUFAs both at the fundamental level in terms of cell signaling
and function (Gorjão et al., 2009; Russell and Bürgin-Maunder,
2012), and also in diseases such as cancer, insulin resistance, and
cardiovascular disease (Anderson and Ma, 2009; Mozaffarian
and Wu, 2012). The aim of this current article is to review the
effects of the different long-chain omega-3 PUFAs in the brain
in normal aging and neurodegenerative disorders. Although the
short-chain omega-3 PUFAs, α-linolenic acid (ALA, 18:3n-3)
and stearidonic acid (SDA, 18:4n-3) have shown potential health
benefits (Barceló-Coblijn and Murphy, 2009; Whelan, 2009),
these have yet to be sufficiently explored in the context of central
nervous system (CNS) disorders, and therefore this review will
be restricted to EPA, DPA and DHA.
EPA, DPA and DHA Metabolism
The omega-3 PUFA series begins with ALA with the other
omega-3 PUFAs derived from ALA via a series of desaturation,
elongation and ultimately β-oxidation reactions (Moore et al.,
1995; Gregory et al., 2011), summarized in Figure 1. The pathway
begins with the desaturation of ALA to SDA by ∆6 desaturase
(encoded by FADS2 genes), which is a rate limiting step. This
is followed by elongation (ELOVL1 gene) to eicocosatetraenoic
acid (20:4n-3). Desaturation by ∆5 desaturase (FADS1 gene)
produces EPA and EPA is then elongated by elongase-2
(ELOVL2 gene) first to DPA and then tetracosapentaenoic acid
(24:5n-3). Tetracosapentaenoic acid then undergoes a second∆6
desaturation to produce tetracosahexaenoic acid (24:6n-3). These
initial steps occur in the endoplasmic reticulum; however, the
final stage of DHA synthesis occurs in the peroxisome following
translocation. In the peroxisome 24:6n-3 is shortened to DHA
(22:6n-3) by a single round of β-oxidation by the action of
acyl-coenzyme-A oxidase (ACOX1 gene), D-bifunctional enzyme
(HSD1784 gene) and then peroxisomal thiolases.
FIGURE 1 | Synthesis of EPA, DPA and DHA from ALA. The longer
chain omega-3 polyunsaturated fatty acids (PUFAs) are synthesized from
ALA by a progressive series of enzymatic desaturation and chain
elongation steps, initially in the endoplasmic reticulum. In the final stage
tetracosahexaenoic acid (24:6n-3) is translocated to the peroxisome and is
shorted by one cycle of the β-oxidation pathway to form DHA (22:6n-3).
For further details refer to the text. Figure adapted from Dyall and
Michael-Titus (2008).
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TABLE 1 | Summary of the metabolism, neuroprotective and anti-inflammatory effects of DPA*.
Experimental model Main outcomes Reference
Metabolism
Sprague Dawley rats DPA increased DPA in all tissues and DHA in the liver. DPA also partly retro-converted to EPA in liver, adipose
tissue, heart and skeletal muscle.
Kaur et al. (2010)
Sprague Dawley rats DPA increased DPA in heart and liver and increased EPA content with the retro-conversion particularly
pronounced in the kidney.
Holub et al. (2011)
Wistar rats DPA and DHA β-oxidized significantly less than EPA at 6 h, and higher incorporation of DPA and DHA in
skeletal muscle and heart than EPA.
Kaur et al. (2013)
Sprague Dawley rats Greater excretion of DPA in feces than EPA. EPA and DPA similarly increased EPA, DPA and total long chain
omega-3 PUFAs in the liver.
Ghasemi Fard et al. (2014)
Healthy females
(age 21–30 years)
After 4 days supplementation DPA increased EPA, DPA and DHA content of plasma or RBC lipids, whereas
EPA only increased EPA content.
Miller et al. (2013)
Healthy females
(age 20–30 years)
EPA and DPA metabolized differently postprandially. DPA significantly decreased chylomicronemia compared
to EPA.
Linderborg et al. (2013)
Neuroprotection
Young (3–4 months)
and old (20–22 months)
rats
EPA increased cortical tissue DPA and DHA in young and old rats and EPA in old rats, whereas DPA
increased DPA in young and old rats and DHA in young rats. EPA and DPA similarly down-regulated age-
related microglial activation, decreased activation of sphingomyelinase and caspase 3 and restored long-term
potentiation and improved spatial memory in the aged rats.




DPA-derived PD1n-3 DPA significantly reduced neutrophil recruitment during peritonitis of mice and stimulated
macrophage phagocytosis and clearance of apoptotic human neutrophils, both to a similar extent to DHA-
derived PD1.
Aursnes et al. (2014)
Human macrophages DPA-derived Mar1n-3 DPA stimulated macrophage phagocytosis and clearance of apoptotic human
neutrophils to a similar extent to that of DHA-derived Mar1.
Tungen et al. (2014)
* For a detailed review of the metabolism and biological effects of DPA prior to 2011 see Kaur et al. (2011).
Although this pathway is now well characterized, the
efficiency and kinetics of conversion in humans has been
somewhat harder to establish. There are limited tissues readily
available for analysis, so blood components are typically
analyzed, which although showing strong correlations with
peripheral tissues, may not reflect the composition of the CNS
(Tu et al., 2013). Furthermore, it has long been known that
blood components differ in their metabolism and incorporation
of EPA, DPA and DHA (Brown et al., 1991). In an early short-
term fish oil supplementation study erythrocyte EPA was a
stronger indicator of omega-3 PUFA intake than DPA or DHA,
potentially due to differential incorporation into the membrane
phospholipids. EPA content appears to be largely determined
by exchange with plasma lipoproteins, whereas DPA and DHA
are more enriched in the inner membrane and are therefore
more influenced by erythrocyte turnover (Brown et al., 1991).
More recently these different incorporation rates and efficiencies
have also been shown in other blood components (Metherel
et al., 2009; Miller et al., 2013). For example, when participants
were given 8 g of pure EPA or DPA over a 7 day period, EPA
supplementation significantly increased EPA in erythrocytes and
plasma cholesterol esters and phospholipids, but not plasma
triacylglycerols. Whereas, DPA supplementation significantly
increased DPA in plasma triacylglycerols and phospholipid
fractions, but not erythrocyte or plasma cholesterol esters (Miller
et al., 2013). These differential efficiencies of incorporation are
not be restricted to blood and are also seen in adipose tissue
(Katan et al., 1997). Recent studies investigating the differences
in metabolism between EPA, DPA and DHA are summarized
in Table 1, where it appears a potential role for DPA may be to
act as a reservoir for EPA and DHA. Earlier studies have been
extensively reviewed by Kaur et al. (2011).
It has also been demonstrated that variations in genes
involved in the biosynthesis and metabolism of omega-3 PUFAs
affects their blood levels. In a study of 8866 participants from
European ancestry single nucleotide polymorphisms (SNPs)
in desaturase genes FADS1 (∆5 desaturase) and FADS2 (∆6
desaturase) were associated with higher ALA and lower EPA
and DPA plasma phospholipid levels, suggesting different rates
of conversion (Lemaitre et al., 2011). Similarly, higher levels
of EPA and DPA and lower DHA were associated with SNPs
in ELOVL2 (elongase 2). Furthermore, those with the apoE-
ε4 (ApoE-ε4) polymorphism show a lower response to EPA
and DHA supplementation (Plourde et al., 2009), and disturbed
DHA metabolism, such that DHA has a significantly decreased
half-life and enhanced β-oxidation (Chouinard-Watkins et al.,
2013). The ApoE-ε4 allele is the major genetic risk factor for
the development of late onset AD (Hauser and Ryan, 2013), and
importantly ApoE-ε4 carriers seem not to be protected against
AD when consuming fish (Chouinard-Watkins et al., 2013).
Gender also appears to differentially affect long-chain omega-3
PUFA levels, whereby females have significantly lower blood
levels of DPA and EPA, but significantly higher DHA than males
(Metherel et al., 2009).
These individual variations in response also extend to
changes in the levels of omega-6 and omega-3 PUFA-derived
metabolites (Nording et al., 2013). In this detailed lipidomics
analysis 12 subjects were given 1.9 g/day EPA and 1.5 g/day
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DHA for 6 weeks. There were some shared responses to the
supplementation with the participants, such as significantly
decreased plasma triacylglycerols, very low density lipoproteins
(VLDLs) and chylomicron particles. However, there was also a
very high degree of inter-individual variability in the effects of
supplementation on the production of omega-6 and omega-3
PUFA-derived metabolites. For example, production of the EPA
lipoxygenase (LOX) metabolite 12-hydroxyeicosapentaenoic
acid (12-HEPE) varied between subjects from an 82% decrease
to a 5,000% increase.
However, in spite of these individual variations, studies
into the effects of omega-3 PUFA supplementation on blood
composition in normal healthy adults consuming Western diets
do show some consistent responses (Arterburn et al., 2006;
Brenna et al., 2009). ALA supplementation induces significant
increases in EPA and DPA content, but has negligible effects
on DHA content in plasma or blood cells (in the order of 1%
in infants and much lower in adults). EPA supplementation
increases blood EPA and DPA levels to an approximately
15-fold greater extent than ALA, but also does not affect DHA.
Only pre-formed DHA supplementation significantly increases
blood DHA levels (Brenna et al., 2009). Consequently the most
consistent way to increase EPA, DPA or DHA blood content is to
supplement with that particular PUFA. However, care does needs
to be taken when comparing between studies and extrapolating
from blood to CNS levels.
EPA, DPA and DHA Metabolism in the Brain
The brain has a unique fatty acid composition with high
levels of palmitate (16:0), the omega-6 PUFA arachidonic acid
(AA, 20:4n-6), and DHA, but low levels of other omega-3
PUFAs, especially EPA (Crawford et al., 1976; Brenna and
Diau, 2007). Indeed, brain EPA levels are typically 250–300
times lower than DHA (Chen et al., 2009). Thus, DHA
is quantitatively the most important omega-3 PUFA in the
brain. In addition to differences in tissue levels of EPA, DPA
and DHA, there are also differences in their phospholipid
location within the brain, such that DHA and DPA are
predominantly enriched in phosphatidylethanolamine (PE)
and phosphatidylserine (PS), whereas EPA appears preferably
esterified to phosphatidylinositol (PI; Chen et al., 2009). Indeed,
EPA shares this proclivity for PI with the AA, which is also highly
enriched in PI (Lee and Hajra, 1991), and may be related to their
equivalent chain length.
The endogenous synthesis of EPA, DPA and DHA are
low within the brain compared with uptake from the plasma
unesterified fatty acid pool (Demar et al., 2005, 2006), suggesting
that the brain maintains levels via the uptake from dietary and/or
liver sources in plasma. Using an in situ cerebral perfusion
competition assay, EPA and DHA were found to enter the
brain at similar rates, and therefore appear to cross the blood
brain barrier by simple diffusion (Ouellet et al., 2009), and
presumably DPA acts in the same manner. The low levels
of EPA are maintained by multiple mechanisms including
β-oxidation, decreased incorporation, elongation to DPA and
lower phospholipid recycling (Chen et al., 2013; Kaur et al., 2013).
It is currently unclear why brain phospholipids are specifically
enriched in DHA and low in DPA and EPA. As described
above, biosynthesis of DHA from DPA involves elongation
and desaturation, followed by translocation to the peroxisome
for β-oxidation. This is not only more energetically costly,
but also introduces PUFAs into the membrane with much
greater potential for peroxidation. Furthermore, this specific
DHA enrichment is conserved across species (Crawford et al.,
1976; Farkas et al., 2000), suggesting that there a highly specific
requirement for DHA in the neuronal membrane.
Effects of EPA, DPA and DHA on Neuronal
Membrane Properties
A variety of membrane effects have been shown with DHA,
including modulating key biophysical properties such as acyl
chain order, membrane fluidity, phase behavior, compression,
permeability, fusion, flip-flop and protein activity (Stillwell
and Wassall, 2003; Stillwell et al., 2005), and driving the
creation of cholesterol-depleted domains (Wassall and Stillwell,
2008). However, there have been few direct comparisons of
the membrane properties of EPA, DPA and DHA, to explain
this indispensable role, although recently DHA and EPA were
shown to partition differently in raft and non-raft domains
in membranes (Williams et al., 2012). DHA had a much
greater tendency to accumulate into sphingomyelin/cholesterol-
rich lipid rafts than EPA, and therefore had a much greater
potential to affect cell signaling by modify the composition of
these lipid rafts. A further intriguing recent hypothesis for the
indispensable nature of DHA suggests that the unique structure
of DHA allows for the quantum transfer and communication of
pi-electrons across the membrane (Crawford et al., 2013). This
hypothesis offers an explanation for the precise depolarisation of
retinal membranes and the cohesive, organized neural signaling
essential for higher intelligence.
An important role for DHA in the membrane is to modulate
the synthesis of PS, as the accumulation and biosynthesis of PS
in neuronal tissues is sensitive to the level of membrane DHA
(Garcia et al., 1998) and 18:0, DHA is the most abundant PS
species in the brain (Kim et al., 2014a). The biosynthesis of PS
occurs from pre-existing phosphatidylcholine (PC) or PE via
serine base exchange, and DHA at the sn-2 position on PC is
more favorably converted to PS (Kim et al., 2004). Increasing
the PS content of neuronal membranes may positively affect
neuronal survival via the PI 3-kinase/Akt signaling pathway
(Akbar et al., 2005). However, when directly compared, dietary
EPA and DHA similarly increase brain phospholipid levels
(Cansev and Wurtman, 2007). Gerbils fed EPA or DHA (300
mg/kg/day by oral gavage) had significantly increased brain
levels of PE, PS and PI compared to animals on the control
diet. The DHA group also had significantly increased PC levels.
These effects were accompanied by increases in the levels of pre
and post-synaptic proteins, syntaxin-3, PSD-95 and synapsin-1,
and were not seen with following AA treatment. In addition
to the accumulation of phospholipids DHA has further effects
on membrane phospholipid composition. A detailed lipidomics
analysis found that rats supplemented with 10 mg/day of
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DHA for 8 weeks induced multiple changes in phospholipid
composition, including the production of new PS and PI species
(Little et al., 2007).
The indispensable nature of DHA in neuronal membranes has
also been shown by omega-3 PUFA dietary deficiency studies,
whereby reduction of brain phospholipid DHA consistently
produces reciprocal increases in the levels of DPAn-6 (Enslen
et al., 1991; Contreras et al., 2001). Since omega-3 and
omega-6 PUFAs are recycled independently of each other, this
relationship is probably maintained through competition for
∆6D (Contreras et al., 2001). Omega-3 PUFAs competitively
inhibit the desaturation of linoleic acid (18:2n-6) by ∆6D
(Galli et al., 1971), and therefore subsequent biosynthesis of
longer chain omega-6 PUFAs. This reciprocal relationship
maintains the degree of phospholipid membrane unsaturation to
approximately constant levels, in a process called ‘‘homeoviscous
compensation’’ (Garda et al., 1994). However, in spite of this
homeoviscous compensation profound and widespread effects
are observed when tissue DHA levels are decreased, such
as alterations to membrane properties (Eldho et al., 2003),
decreases in performance in tasks of spatial memory (Lim
et al., 2005), altered enzyme activity and electrophysiological
properties (Bourre et al., 1989), and altered neurotransmission
(Able et al., 2014; Cardoso et al., 2014).
Overall, these studies highlight the unique and indispensable
role of DHA in neuronal membranes, whereas, the only
established unique role for EPA is as a precursor to the
three series eicosanoids and related peroxy-fatty acids, although
specific therapeutic effects have been putatively identified across
a range of neurological conditions. Similarly, bioactive roles for
DPA are now being described. The remainder of this review will
explore the evidence for both specific and complementary effects
of EPA, DPA and DHA in the brain.
EPA, DPA and DHA Derived Lipid
Mediators
It is well established that omega-3 PUFA derived lipid
mediators play a key role in the inflammatory response. These
enzyme-derived mediators are a varied group of oxygenated
forms of the C20 and C22 omega-3 PUFAs. The classic
lipid mediators include prostaglandins and leukotrienes (LT),
and two structurally distinct new classes of mediators have
been identified. The first are called ‘‘Specialized Pro-resolving
Mediators’’ (SPMs; Bannenberg and Serhan, 2010), and the
second are electrophilic fatty acid oxo-derivatives (Groeger et al.,
2010; Cipollina et al., 2014).
The classic lipid mediators are a varied group of oxygenated
forms, with those derived from the C20 PUFAs, such as
EPA, called eicosanoids, whereas those from C22 DPA
and DHA called docosanoids. Biosynthesis is catalyzed by
three enzyme systems: cyclooxygenase (COX, also known
as prostaglandin endoperoxide H synthase or PGHS) and
subsequent synthases, LOX and cytochrome P450 mixed-
function oxidase enzymes (CYP450; Smith et al., 2000). COX
catalyzes the initial oxygenation of non-esterified PUFAs to
produce prostaglandin H (PGH), a short-lived intermediate,
which is further metabolized to other prostaglandin series (PG),
prostacyclins (PGI), thromboxanes (TXA), LT, lipoxins (LX),
hydroxy and hydroperoxy fatty acids (Smith et al., 2000).
Vertebrates have two principal isoforms of COX: COX-1 and
COX-2 (Kulmacz et al., 2003).
In most tissues COX-1 is constitutively expressed, whereas
COX-2 is inducible. However, in specialized cell types such
as the neurones in the CNS, constitutive COX-2 expression is
observed in the cortex and allocortical structures, such as the
hippocampus and amygdala (Breder et al., 1995). COX-2 is
particularly enriched in the hippocampus and cortex (Yamagata
et al., 1993), where expression is localized in the postsynaptic
dendritic spines (Kaufmann et al., 1996), suggesting a role in
neural activity and activity-dependent plasticity. COX-1 and -2
have similar structures, although COX-1 has a smaller active site
(Rowlinson et al., 2000). This size restriction imposes a substrate
specificity on COX-1 for C20 fatty acids (Kulmacz et al., 2003),
and is unable to oxygenate DHA (Corey et al., 1983). The COX-2
active site is about 20% larger (Smith et al., 2000) and this enzyme
is consequently able to metabolize a larger range of substrates,
with differing acyl chain length and degree of unsaturation,
potentially including DPA and DHA.
The SPMs are a rapidly expanding class of autacoid molecules
involved in the active resolution of inflammation, and are
produced through COX and LOX pathways (Serhan et al.,
2008). EPA produces E-series resolvins (RvE), whereas DHA
produces docosanoids, such as protectins, D-series resolvins
(RvD) and maresins (MaR; Serhan et al., 2015). Recently
analogous mediators to DHA-derived D-series resolvins,
protectins and MaRs have been identified from DPA, and
include RvD1n-3 DPA, MaR1n-3 DPA and related products (Dalli
et al., 2013). PD1n-3 DPA and MaR1n-3 DPA have recently been
synthesized and demonstrate potent anti-inflammatory and
pro-resolving properties, with comparable actions to EPA and
DHA-derived resolvins in murine models of acute inflammation
and human leukocytes (Aursnes et al., 2014; Tungen et al., 2014).
The rapidly expanding repertoire of oxygenated metabolites
from EPA, DPA and DHA and the similarity between their
isomers has the scope for confusion in assigning biological
properties, and it has been suggested that care needs to be taken
when interpreting the literature (Balas et al., 2014).
The SPMs act via a series of cell-type specific receptors, which
due to space restraints are beyond the scope of this review;
however, the reader is directed to a number of excellent reviews
by Dr. Charles Serhan, whose laboratory has led research in this
area (Serhan et al., 2009; Bannenberg and Serhan, 2010; Dalli
et al., 2013; Serhan and Chiang, 2013). However, by way of a brief
example, RvE1 binds the orphan receptor ChemR23, and BLT1, a
leukotriene B4 receptor, whereas RvD1 binds GPR32 and ALX, a
lipoxin A4 receptor. This specificity may allow for specific effects
of EPA, DPA and DHA-derived SPMs. The best characterized
SPM in terms of nervous system protection is (neuro)protectin
D1 ((N)PD1, 10R-17S-dihydroxy-docosahexaenoic acid), which
is biosynthesized in response to injury and may have therapeutic
potential in a wide range of neurological conditions (Bazan et al.,
2011b; Bazan, 2013). The unique neuroprotective potential of
EPA and DPA-derived SPMs remains to be elucidated.
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A further novel class of anti-inflammatory lipid mediators
derived from EPA, DPA and DHA has recently been described
(Groeger et al., 2010; Cipollina et al., 2014). These are
electrophilic fatty acid oxo-derivates (EFOX) synthesized by
COX-2 and 5-LOX, and include 5-oxo-EPA, 7-oxo-DPA
and 7-oxo-DHA, from EPA, DPA and DHA, respectively.
In the first charactrerisation of their actions EFOXs were
shown to have a wide range of anti-inflammatory actions,
including acting as agonists of the nuclear transcription factor,
peroxisome proliferator-activated receptor gamma (PPARγ),
activating Nrf2-dependent antioxidant reponses and inhibiting
cytokine production and inducible nitric oxide expression in
activated macrophages (Groeger et al., 2010). Importantly,
dietary supplementation with 1 g EPA and 0.4 g DHA per day
for 4 months significantly increases the formation of 5-oxo-EPA
and 7-oxo-DHA (Cipollina et al., 2014), and consitent with the
formation of resolvins from DHA (Serhan et al., 2002), aspirin
acetylation of COX-2 also significantly increases production of
EFOXs. Although independent roles of the different EFOXs
have yet to be described, these observations suggest these newly
reported lipid mediators needs to be considered when assiging
anti-inflammatory and pro-resolving effects to EPA, DPA and
DHA. The multiple lipid mediators derived from EPA, DPA and
DHA are summarized in Figure 2.
Effects of EPA, DPA and DHA on Brain
Plasticity
Neurite Outgrowth and Synaptogenesis
The synapse and nerve growth cone are two structures that
play key roles in development and nervous system repair,
furthermore, slow neurodegenerative processes in the CNS are
accompanied by significant damage to neurite (Robson et al.,
2010). The effects of EPA and DHA, but not DPA have been
studied on neurite outgrowth and synaptogenesis in a variety
of cell types and stages of development. Early studies focused
on DHA, and found beneficial effects on neurite outgrowth
in terms of overall length and complexity of outgrowth in
rat pheochromocytoma-12 (PC-12) cells (Ikemoto et al., 1997),
rat embryonic hippocampal primary cultures (Calderon and
Kim, 2004) and rat embryonic cortical neurons (Cao et al.,
2005). In addition to enhanced neurite outgrowth, DHA also
promotes synaptogenesis and synaptic expression of synapsin,
and glutamate receptors in rat hippocampal neurones (Cao et al.,
2009). Work in our laboratory directly compared the neurite-
promoting effects of DHAwith EPA in primary sensory neuronal
cultures from young (post-natal day 3 and 9), adult (2–4 months)
and aged (18–20month) rats (Robson et al., 2010). Both EPA and
DHA increased neurite outgrowth in the developmental stages;
however, only DHA produced positive effects in the tissue from
aged rats, which possess a significantly lower degree of plasticity
than tissues from immature animals.
Neurogenesis
Adult neurogenesis is the process by which new neurons are
generated from neural stem cells and progenitor cells and has
been consistently shown to occur in two areas of the adult
brain, the subventricular zone of the lateral ventricles and the
subgranular layer of the hippocampal dentate gyrus (Ehninger
and Kempermann, 2008). Aging is the greatest negative regulator
of neurogenesis (Kuhn et al., 1996), and there is a strong
correlation between age-related impairments in hippocampal-
dependent memory tasks and the decline in neurogenesis
(Drapeau et al., 2003). Conversely, increased neurogenesis in
reported in rodents following ischemia (Takagi et al., 1999),
stroke (Darsalia et al., 2005) and after seizures (Parent et al.,
1997). These increases in neurogenesis may be an attempt
at brain self-repair and raises the intriguing possibility that
enhancing neurogenesis and the subsequent survival of new
neurons may have significant therapeutic potential.
In vitro DHA has consistently been shown to promote the
differentiation of neural stem cells into neurons (Kawakita
et al., 2006; Katakura et al., 2009); however, comparisons of
the pro-neurogeneic effects of different omega-3 PUFAs have
only recently begun to be explored in the literature. In the first
direct comparison 1 µM DHA and EPA were both reported to
enhance differentiation of neural stem cells to a similar extent
(Katakura et al., 2013). However, they had divergent effects on
the transcription factors involved in regulating the cell cycle.
EPA significantly increased the levels of Hes1, whereas with
DHA levels were significantly decreased. Hes1 is a repressor type
transcription factor, which inhibits neuronal differentiation and
enhances proliferation in neural stem cells (Katakura et al., 2013).
Also, EPA, but not DHA, significantly increased Hes6, which
acts in a positive-feedback loop with Hes1 to promote neuronal
differentiation. Preliminary work in our laboratory also suggests
divergent effects of EPA and DHA on neurogenesis; however,
in this study 10 nM EPA significantly increased proliferation,
whereas with 10 nM DHA it was decreased, consistent with a
role in differentiation (Mandhair et al., 2013). It may be that the
effects of EPA and DHA in regulating neural stem cell fate are
based on a fine balance between their respective effects at basic
helix-loop-helix transcription factors.
Although the addition of EPA and DHA show regulatory eff-
ects on neural stem cell fate, it is currently unclear whether
these are direct effects of EPA and DHA or their
metabolites. The DHA endocannabinoid-like metabolite,
N-docosahexanoylethanolamine (DHEA, also known as
synaptamide) induces neuronal differentiation of neural stem
cells by activation of protein kinase A (PKA)/cAMP response
elementbindingprotein (CREB;Rashidet al., 2013). Furthermore,
the oxygenated DHA-derivative NPD1 has also been shown to
promote neuronal differentiation of embryonic stem cells (Yanes
et al., 2010). Overall however, these results suggest that the
regulatory effects of EPA and DHA directing neural stem cell fate
are mediated via divergent effects at transcription factors and
potentially different signalingpathways, andmaybe at least inpart
mediated by their enzymatic conversion to bioactive mediators.
Normal Brain Aging and Alzheimer’s
Disease
Many widespread changes characterize normal brain aging, such
as increased oxidative stress (Perluigi et al., 2014), mitochondrial
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FIGURE 2 | Summary of the lipid mediators derived from (A) EPA,
(B) DPA and (C) DHA. In the classical “canonical” pathway EPA is initially
converted to the intermediate prostaglandin G2 (PGG2) by either COX-1 or -2
and then enzymatically to the 3 series prostaglandins, prostacylcins or
thromboxanes. EPA can also be converted by 5-lipoxygenase (LOX) to
5-hydroperoxyeicosapenataenoic acid (5-H(p)EPE), which can then either be
converted by 5-LOX to leukotriene A5 (LTA5) and then by Leukotriene A4
Hydrolase (LTA4) to leukotriene B5 (LTB5) or to 5-hydroxyeicosapentaenoic
acid (5-HEPE), which is then converted into 5-oxo-EPA by
5-hydroxyeicosanoid dehydrogenase (5-HEDH). EPA can also be sequentially
converted by cytochrome P450 (CYP450) enzymes to
18R-hydroxyeicosapentaenoic acid (18R-HEPE) and then by 5-LOX to
E-series resolvins (RvE). COX-2 can also convert EPA to the electrophilic fatty
acid oxo-derivative electrophilic fatty acid oxo-derivates (EFOX)-D5, in a
process enhanced by aspirin acetylation of COX-2. Aspirin acetylation of
COX-2 also produces 18S- and 18R-hydroperoxyeicosapentaenoic acids
(18S-, or 18R-HETE) from EPA, which are either converted by 5-LOX to
aspirin-triggered 18S-resolvin E1 and resolvin E1 (AT-18S-RvE1 and
AT-RvE1), respectively, or through an extra step by LTA4H to AT-18S-RvE2
and AT-RvE2. Analogous series of resolvins, maresins, and EFOXs produced
from DPA to those from DHA have recently been identified; however, the
nature of the enzymatic conversions remains to be elucidated. DHA is
converted to 17S-hydroperoxydocosahexaenoic acid (17S-H(p)DHA) by
15-LOX, which is converted by 5-LOX to D-series resolvins (RvD), or
enzymatically hydrolysed to (neuro)protectin D1 ((N)PD1. DHA can also be
converted by 12 or 15-LOX via 14-hydroperoxydocosahexaenoic acid
(14-H(p)DHA) to the maresins. DHA can also be converted by 5-LOX to
7-hydroxydocosahexaenoic acid (7-HDHA) and then by a dehydrogenase to
7-oxo-DHA, with 5-HEDH a likely candidate, or by COX-2 to EFOX-D6, which
is enhanced by aspirin acetylation. Acetylation also produces
17R-hydroperoxyDHA, which can then be converted to aspirin triggered
resolvins and protectins.
dysfunction and alterations in energy metabolism (Ames, 2004)
and damage to DNA (Canugovi et al., 2013). There are also
age-related structural changes including a reduction in brain
volume and weight (Anderton, 2002) and altered membrane
lipid content (Svennerholm et al., 1997). The aging brain is
more prone to the development of neurodegenerative diseases,
such as Alzheimer’s disease (AD), and with the slow developing
preclinical phases of these diseases it may be difficult to
distinguish what are age-related changes and what are effects
of the undetected disease (Fjell et al., 2014). AD is the most
common form of dementia in the older person, with a prevalence
of about 4.4% of the population over 65 years of age (Ward
et al., 2012) and affects cognitive function, mood and behavior
(Selkoe et al., 2012). The characteristic pathological features
of AD are neurofibrillary tangles, which are mainly composed
of aggregates of hyperphosphorylated tau protein and senile
plaques containing amyloid β-protein (Aβ; Lloret et al., 2015).
The etiology and pathogenesis of the disease is currently not
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well understood, andmanagement is mostly symptomatic, aimed
at ameliorating the cognitive deficits (Selkoe et al., 2012).
Furthermore, a recent meta-analysis has shown that relatively
few clinical trials are being undertaken for AD therapeutics, and
the number of compounds progressing to regulatory review is
among the lowest found in any therapeutic area (Cummings
et al., 2014), highlighting the importance of developing new
therapeutic approaches in this area.
Fatty Acid Composition
Several studies have investigated the relationship between blood
EPA, DPA and DHA levels and risk of cognitive decline. Higher
plasma EPA, but not DHA, was found to be associated with lower
gray matter atrophy of the hippocampal/parahippocampal area
and amygdala of community dwellers aged 65 years and older
(Samieri et al., 2012), and higher plasma EPA, but not DPA or
DHA, was also associated with slower cognitive decline (Samieri
et al., 2011), dementia risk (Samieri et al., 2008) and depressive
symptom risk in the elderly (Feart et al., 2008). Furthermore, a
recent meta-analysis found that although blood EPA, DHA and
total omega-3 PUFA are significantly decreased in patients with
dementia, only EPA was significantly lower in patients with pre-
dementia syndrome, leading the authors to suggest that EPAmay
by a biomarker and indeed risk factor for age-related cognitive
impairment (Lin et al., 2012a). However, others have shown a
reduced risk of developing all-cause dementia associated with
higher plasma DHA, not EPA (Schaefer et al., 2006). In this study
those in the top quartile of plasma PC DHA level were associated
with a significant 47% reduction in risk. Furthermore, a recent
cross-sectional analysis of 1575 dementia-free participants also
found only lower erythrocyte DHA, but not EPA, associated
with significantly smaller brain volumes and lower scores in
tests of visual memory, executive function and abstract thinking
(Tan et al., 2012). These inconsistencies between observations are
likely due to the issues described above limiting the efficacy of
using blood fatty acid levels as a surrogate biomarker for CNS
levels.
In order to address some of these issues, a recent innovative
study investigated the differences in fatty acid content of matched
plasma and brain cortex samples from post-mortem samples
from subjects with no cognitive impairment, mild cognitive
impairment and AD (Cunnane et al., 2012). To date this has been
the only study to directly compare plasma and brain levels from
the same subjects. In the AD group DHA, but not EPA or DPA,
was found to be higher in the plasma cholesteryl esters and lower
in plasma phospholipids. In the brain, DHA was lower only in
PS of the mid-frontal cortex and superior temporal cortex of AD
subjects compared to non-cognitively impaired. Interestingly,
there was only one significant correlation between plasma and
brain fatty acid samples and this was between DHA in plasma
total lipids and DHA in PE of the angular gyrus, but this was only
seen in the subjects with mild cognitive impairment. Overall,
these results suggest that the fatty acid content of plasma from
subjects with mild cognitive impairment or AD may not reflect
the content of the brain cortex.
Astatrita and coworkers investigated the role of liver DHA
biosynthesis in the altered brain DHA content seen with AD
patients (Astarita et al., 2010). Liver DHA content was lower
in AD patients than control subjects, whereas EPA, DPA and
tetracosahexaenoic acid (24:6n-3), were significantly elevated.
Consistent with these changes, expression of peroxisomal
D-bifunctional protein was reduced; suggesting decreased activity
of this enzyme is involved in impairedDHAbiosynthesis, thereby
lessening the flux to the brain. However, the relative contribution
of DHA biosynthsized by the liver compared to that provided by
dietary intake remains to be established, as does the overall effect
of this on blood DHA levels.
Inflammation, Learning and Memory
The aging brain is particularly prone to inflammatory and
oxidative alterations, which may underlie decreases in learning
and memory, as manifested in the age-related deficits in
long-term potentiation (LTP; Lynch, 2004). LTP is an
electrophysiological property of certain neuronal circuits
that is used as a model for investigation of the pathways
underlying activity driven neuronal and synaptic plasticity,
learning and memory (Bliss and Collingridge, 1993). Dietary
enrichment of aged-rats with EPA, DHA and more recently
DPA have all been shown to have positive effects on age-related
impairments in LTP, and these effects are likely mediated via
multiple anti-inflammatory effects acting via alterations in
cytokine levels. For example, 8 weeks dietary supplementation
with 10 mg/day DHA reverses age-related impairments in
LTP and depolarization-induced glutamate release (McGahon
et al., 1999). Similarly, feeding rats diets supplemented with
EPA for 8 weeks (10 mg/day for 3 weeks and 20 mg/day
for 5 weeks) prevented age-related increases in cortical and
hippocampal IL-1β and restores LTP (Martin et al., 2002),
age-related increases in IL-1β-induced signaling and decreases
in IL-4, and extracellular-signal-regulated kinases (ERK) and
PI-3 kinase (Maher et al., 2004). 125 mg/day EPA for 4 weeks
also attenuated age-related increases in hippocampal IL-1β,
interferon-γ, and decreases in IL-4 (Lynch et al., 2007). EPA also
protects aged rats from amyloid-β (Aβ) induced increases in
hippocampal IL-1β, potentially mediated by positive effects on
the PPARγ nuclear transcription factor (Minogue et al., 2007).
This group also recently compared the effects of DPA with EPA,
where similar neuroprotective effects were reported (Kelly et al.,
2011). In this study both DPA and EPA (200 mg/kg/day) were
equally potent at reversing age-related impairment in spatial
learning and LTP, and showed similar abilities to decreases
in age-related microglial activation and associated oxidative
stress.
Significant advances have been made in our understanding of
the role of DHA and DHA-derived anti-inflammatory mediators
such as neuroprotection (NPD-1) in brain cell survival and repair
in the aging and AD brain (e.g., Bazan et al., 2011a). However,
few studies have made direct comparisons with EPA or DPA
or their metabolites. A recent study has however compared
the relative anti-inflammatory effects of EPA and DHA in
vitro in peripheral blood mononuclear cells from AD patients
compared with healthy controls (Serini et al., 2012). The addition
of either EPA or DHA (10–20 µM) significantly reduced the
induced-cytokine release. Although DHA consistently showed
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a more pronounced effect than EPA, DHA reduced only the
high IL-1β/IL-10 ratio, whereas EPA also reduced the IL-6/IL-10
ratio. Overall, DHA had a more powerful inhibitory effect on
individual inflammatory cytokines; however, EPA was better
at changing the proinflammatory profile of the cells from
AD patients to a profile closer to that found in the healthy
controls.
Clinical Trials
To date clinical trials with omega-3 PUFAs in healthy older
adults, individuals with mild cognitive impairment or AD have
tended to use mixed EPA and DHA preparations at different
ratios, and have been reviewed extensively elsewhere (Jiao
et al., 2014). There have however been a limited number of
trials using either highly enriched EPA or DHA preparations.
An early open-label pilot study treated AD patients (MMSE
scores 10–24) aged 65 and over with 1 g/day EPA treatment
for 12 weeks (Boston et al., 2004). This short-term treatment
significantly increased erythrocyte EPA and DPA, but not DHA,
and there was no difference between treatment and baseline
scores in cognitivemeasures. In amore recent randomized-blind,
placebo-controlled study participants with mild to moderate AD
(MMSE scores 14–26) were supplemented with 2 g/day DHA for
18 months (Quinn et al., 2010). The DHA supplementation did
not slow the rate of cognitive decline compared to the placebo,
although there may have been weak effects with ApoE-ε4 non-
carriers.
More positive effects have been seen in cognitively healthy
participants and participants with mild cognitive impairment.
Yurko-Mauro and colleagues supplemented healthy adults aged
55 years and over with MMSE scores above 26 with 900 mg
DHA or placebo for 24 weeks (Yurko-Mauro et al., 2010).
The treatment significantly improved Paired Associate Learning
(PAL, six pattern errors) and immediate and delayed Verbal
Recognition Memory scores, and plasma DHA levels doubled
and correlated with improved PAL scores in the DHA group.
Similarly, participants with mild cognitive impairment and aged
60 years and over were given either 1.3 g DHA and 0.45 mg
EPA or placebo for 12 months and those in the DHA treatment
group had significant improvements in short-term and working
memory, immediate verbal memory and delayed recall memory
compared to the placebo group (Lee et al., 2013). These results are
consistent with a study showing positive effects in a sub-group of
patients with very mild cognitive impairment (MMSE> 27) who
were given a high DHA supplement (1.7 g DHA and 0.6 g EPA)
for 6 months (Freund-Levi et al., 2006).
There has only been one study to directly compare the
effects of DHA with EPA in participants with mild cognitive
impairment (Sinn et al., 2012). In this 6 month double-blind
randomized controlled trial participants received a supplement
high in EPA (1.67 g EPA and 0.16 g DHA), high in DHA (1.55 g
DHA and 0.40 gDHA) or high in the omega-6 PUFA linoleic acid
(2.2 g). Compared to the linoleic acid group both the EPA and
DHA groups significantly improved their Geriatric Depression
Scores, but only with the DHA group were changes memory
seen, where there were significant improvements in verbal
fluency.
Overall, where individual omega-3 PUFAs have been
investigated in trials of healthy aging, mild cognitive impairment
and AD the focus has been on DHA, which is consistent with
the pre-clinical evidence (Dyall and Michael-Titus, 2008). DHA
treatment appears to show the greatest promise compared to EPA
and DPA, and the beneficial of DHA treatment currently appear
to be to improve memory and learning in participants with
MMSE scores above 26–27, particularly non-ApoE-ε4 carriers,
although support from clinical trials is currently extremely
limited.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after AD and has a prevalence
of about 2% in the older person, and is also associated
with aging (Franco-Iborra et al., 2015). PD affects the basal
ganglia with patients typically experiencing slowed movements
(bradykinesia), muscle stiffness (rigidity), tremor and disturbed
balance (Franco-Iborra et al., 2015). The neuropathology of the
disease includes dopaminergic neuronal loss from the substantia
nigra pars compacta as well as the presence of Lewy bodies,
which are intracellular inclusions largely composed of the
protein, α-synuclein (Kim et al., 2014b). The pathology and
clinical features of PD and AD are markedly different; however,
they do share common mechanism, including mitochondrial
dysfunction (Camilleri and Vassallo, 2014), neuro-inflammation
(Sanchez-Guajardo et al., 2015), and oxidative stress (Xie
et al., 2014). Current symptomatic treatment of PD is based
on correcting dopaminergic signaling, using medications such
as carbidopa/levodopa, dopamine agonists. However, a large
number of patients develop mild to moderate, and occasionally
serious, treatment-associated side-effects, significantly limiting
the efficacy of these treatments (Faulkner, 2014).
Fatty Acid Composition
Purified lipid rafts from the frontal cortex of postmortem samples
from patients with early motor stage PD and incidental PD
exhibit significant reductions in DHA (and AA), but not EPA
or DPA, compared to controls (Fabelo et al., 2011). Whereas, no
differences in the levels of EPA, DPA or DHA were found in
post-mortem analysis of temporal cortex tissue from levodopa-
treated PD patients, or monkeys treated with the Parkinsonian
neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP), compared to their respective matched controls (Julien
et al., 2006). However, significant decreases in DHA were seen
in the temporal cortical fatty acid profile of primates treated
with the MPTP following dyskinesiogenic levodopa treatment,
suggesting the decrease in DHAmay be related to the appearance
of dyskinesia (Julien et al., 2006).
Pre-Clinical Studies
Although there have to date been no clinical trials reported with
supplementation of highly enriched EPA, DPA or DHA in the
treatment PD there have been a number of in vitro and in vivo
studies. Mice were fed for 6 weeks a diet providing 0.8% EPA,
and their brain slices treated with the Parkinsonian neurotoxin
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1-methyl-4-phenylpyridinium (MPP(+)) (Meng et al., 2010).
EPA treatment attenuated the MPP(+) induced increase in AA
content, partially attenuated the striatal dopaminergic turnover,
and prevented the increases of the pro-apoptotic bax and
caspase-3 mRNAs. The treatment significantly increased tissue
EPA and DPA, but not DHA levels, suggesting the effects may
have been mediated directly by EPA and/or DPA. Following
the same dietary paradigm the same group investigated the
effects of EPA in the (MPTP)-probenecid (MPTP-P) mouse
model of PD (Luchtman et al., 2012). EPA treatment attenuated
the MPTP-P induced hypokinesia, ameliorated the procedural
memory deficit and also suppressed the production of striatal
pro-inflammatory cytokines. However, EPA did not prevent
nigrostriatal dopamine loss. The mechanisms behind these
neuroprotective effects of EPA were explored in vitro by the
same group (Luchtman et al., 2013). In MPP(+) treated cells,
EPA was shown to attenuate the reduction in cell viability and
prevent the presence of cytoplasmic inclusions. EPA treatment
also had widespread protective effects, such as attenuating the
MPP(+)-induced increase in Tyrosine-related kinase B (TrkB)
receptors, and down-regulated reactive oxygen species and nitric
oxide, an effect potentially mediated by inhibition of neuronal
NADPH oxidase and COX-2. EPA also attenuated an increase
in the bax:bcl-2 ratio, and cytochrome c release. The effects
of DHA have been explored in MPTP monkeys, where DHA
(100 mg/kg) reduced dyskinesias induced by levodopa without
affecting the anti-Parkinsonian effects, suggesting DHA may
delay the development dyskinesias induced by levodopa, or at
least reduce their severity (Samadi et al., 2006). Protective effects
of DHA have also been shown in mice given a high DHA
diet (5.3 g/kg DHA) and then treated with MPTP (Bousquet
et al., 2008). Following the DHA treatment the dopamine levels
were preserved and the substantia nigral dopaminergic neurons
were protected against losses compared to the controls; however,
motor behavior was not measured.
It should however be noted that DHA treatment may
potentially increase α-synuclein aggregation and the possible
formation of cytotoxic oligomers (De Franceschi et al.,
2011; Yakunin et al., 2012). α-Synuclein is a neuronal
protein that accumulates progressively in PD and related
synucleinopathies. In models systems DHA readily promotes
α-synuclein aggregation in Escherichia coli cells transfected
with the human α-synuclein (De Franceschi et al., 2011).
The α-synuclein oligomers were more toxic if generated in
the presence of DHA in dopaminergic neuronal cell lines.
Furthermore, transgenic mice with the PD-causing A53T
α-Syn mutation fed a diet enriched with 0.69% DHA showed
increased accumulation of soluble and insoluble neuronal
α-synuclein, neuritic injury and astrocytosis (Yakunin et al.,
2012). These α-synuclein oligomers have also been shown
alter membrane permeability in cellular membrane-mimetic
and cell model systems (Fecchio et al., 2013). Further
in vitro analysis suggests that the enhanced α-synuclein
oligomerisation in response to DHA is mediated via the retinoic
X receptor (RXR). DHA is an endogenous ligand of RXRs
(de Urquiza et al., 2000; Egea et al., 2002; Lengqvist et al., 2004)
and aged rats treated with DHA show enhanced RXR expression
(Dyall et al., 2010). Moreover, Lengqvist and coworkers have
shown that other PUFAs such as DPAn-6 and AA are able to
bind and activate RXR in the same range as DHA, indicating RXR
activation is not restricted to DHA, but may also extend to EPA
and DPA.
Overall, there is a lack of clinical trials investigating the role
of EPA, DPA or DHA in PD, although pre-clinical evidence
suggests that EPA may possess therapeutic potential, and may
provide useful adjunctive treatments by alleviating the treatment-
associated dyskinesias. However, a 12 week double-blind placebo
controlled study providing 2 g/day EPA in schizophrenia patients
with established tardive dyskinesia failed to demonstrate any
anti-dyskinetic effects, although modest and transient benefits
were seen in recent onset patients (Emsley et al., 2006). A
clinical trial is currently exploring the role of DHA in reducing
dyskinesia in PD (ClinicalTrials.gov identifier: NCT01563913),
and should help clarify this issue with DHA at least. It is also
important to appreciate that DHA supplementation may have
the potential to worsen the condition. The cytotoxic α-synuclein
aggregating induced by DHA in a variety of models suggests
that caution should be exerted when considering the role of
EPA, DPA and DHA in PD and this area warrants much further
research.
Conclusions
This article has reviewed evidence for individual and shared
neuroprotective effects of EPA, DPA and DHA in aging
and neurodegenerative disorders. EPA, DPA and DHA differ
in important aspects of their biochemistry and metabolism;
however, few studies have made direct comparisons between
their effects. DHA is quantitatively the most important omega-3
PUFA in the brain and has consistently been shown to have
unique and indispensable roles in the neuronal membrane.
However, independent effects for EPA and DPA are being
identified, particularly in regards to their respective anti-
inflammatory mediators. A more detailed characterization of the
individual properties of these mediators, their cognate receptors
and downstream targets may prove essential to increasing
understanding of their specific actions.
Deficits in EPA and DHA levels have been found with
neurodegenerative disorders; however, these have been identified
with varying consistency across studies, and may require a
more detailed appreciation of the role of genetic variability
before a clear picture arises. Although promising therapeutically,
direct evidence from large well-designed intervention studies
into the effects of EPA, DPA and DHA in normal aging and
neurodegenerative disorders is still lacking; however, preliminary
evidence suggests the greatest benefit may been seen with
DHA in non-cognitively impaired older people. It is vital to
consider omega-3 PUFA specific effects when designing and
undertaking systematic reviews and meta-analyses, so treatment
effects are not lost in the aggregation of results. Overall, a greater
understanding of the individual roles of EPA, DPA and DHA in
brain health, protection and repair is needed in order to make
appropriate dietary recommendations and targeted therapeutic
interventions.
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